FTC sues Endo over ‘pay-for-delay’ settlements

The Federal Trade Commission (FTC) has sued Endo Pharmaceuticals for allegedly violating competition laws by agreeing to so-called pay-for-delay settlements surrounding the launch of generic versions of two drugs.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Allergan launches generic version of AstraZeneca cholesterol tablet

5 May 2016 Pharmaceutical company Allergan has received approval from the US Food and Drug Administration to launch a generic version of a cholesterol drug owned by AstraZeneca.

Americas

Endo pays $2.3m to settle states antitrust claims

22 July 2019 Ireland-headquartered Endo Pharmaceuticals agreed to pay $2.3 million to 18 states late last week, settling allegations that the drugmaker paid a competitor to keep a generic version of pain relief drug Lidoderm off the market.

More on this story

Americas

Allergan launches generic version of AstraZeneca cholesterol tablet

5 May 2016 Pharmaceutical company Allergan has received approval from the US Food and Drug Administration to launch a generic version of a cholesterol drug owned by AstraZeneca.

Americas

Endo pays $2.3m to settle states antitrust claims

More on this story

Americas

Allergan launches generic version of AstraZeneca cholesterol tablet

5 May 2016 Pharmaceutical company Allergan has received approval from the US Food and Drug Administration to launch a generic version of a cholesterol drug owned by AstraZeneca.

Americas

Endo pays $2.3m to settle states antitrust claims